In this study, we have detected no HER2-positive CTC in 42 women without BC, ≥1 HER2-positive CTC/22.5 mL in 4.1% of women with DCIS/LCIS and 7.9% of women with M0 BC. Here, ERBB2 is linked to lobular breast carcinoma in situ.